| For: | Xu LN, Zou SQ, Wang JM. Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma. World J Gastroenterol 2005; 11(24): 3719-3723 [PMID: 15968727 DOI: 10.3748/wjg.v11.i24.3719] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v11/i24/3719.htm |
| Number | Citing Articles |
| 1 |
Arthur Zimmermann. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. 2017; doi: 10.1007/978-3-319-26956-6_148
|
| 2 |
Yasushi Adachi, Masanori Nojima, Yingsong Lin, Yoshiharu Masaki, Ayako Murota, Yasushi Sasaki, Hiroshi Nakase, Kenji Wakai, Mitsuru Mori, Akiko Tamakoshi, Masahiko Ando, Yoshihisa Fujino, Shuji Hashimoto, Yoshiharu Hoshiyama, Hiroyasu Iso, Yoshihiro Kaneko, Shogo Kikuchi, Michiko Kurosawa, Haruo Mikami, Kazuya Mikami, Yosikazu Nakamura, Satoe Okabayashi, Kotaro Ozasa, Kiyomi Sakata, Akira Shibata, Koji Suzuki, Koji Tamakoshi, Naohito Tanabe, Ichiro Tsuji, Yasuhiko Wada, Kazumasa Yamagishi, Hiroshi Yatsuya. Serum Soluble Fas Levels and Incidence of Biliary Tract Cancer in a Nested Case–Control Study. Cancer Epidemiology, Biomarkers & Prevention 2026; 35(11) doi: 10.1158/1055-9965.EPI-26-0782
|
| 3 |
Taimei Qu, Lv Tian. RFXANK: A Novel Immune-Related Biomarker for Hepatocellular Carcinoma. Genes 2026; 17(4) doi: 10.3390/genes17040406
|
| 4 |
Qingliang Jiang, Gang Li, Hengyu Li, Xiaoqing Jiang, Daimin Xiang. Multifaceted mechanisms and precision strategies to overcome therapeutic resistance in gallbladder cancer. Critical Reviews in Oncology/Hematology 2026; 219 doi: 10.1016/j.critrevonc.2026.105152
|
| 5 |
Jie Chu, Wei Liu, Xinyue Hu, Huiling Zhang, Jiudong Jiang. P2RY13 is a prognostic biomarker and associated with immune infiltrates in renal clear cell carcinoma: A comprehensive bioinformatic study. Health Science Reports 2023; 6(12) doi: 10.1002/hsr2.1646
|
| 6 |
Sanjeev K. Maurya, Mallika Tewari, Raghvendra R. Mishra, Hari S. Shukla. Genetic abberations in gallbladder cancer. Surgical Oncology 2012; 21(1) doi: 10.1016/j.suronc.2010.09.003
|
| 7 |
Arthur Zimmermann. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. 2016; doi: 10.1007/978-3-319-26587-2_148-1
|
| 8 |
Deeptima Jaiswar, Manjusha Dixit. Molecular convergence in gallbladder cancer: MEK–ERK signalling at the crossroads of oncogenic hubs and pathway cross-talks. Cancer Cell International 2026; 26(1) doi: 10.1186/s12935-026-04349-5
|
| 9 |
Lv Tian, Huifang Zeng, Lin Tian, Huijing Wang, Wei Liu. UNC93B1: a novel immune−related prognostic biomarker in breast cancer. Discover Oncology 2025; 16(1) doi: 10.1007/s12672-025-03124-8
|
| 10 |
Lv Tian, Yiming Wang, Jiexin Guan, Lu Zhang, Jun Fan. The Prognostic Value and Immunomodulatory Role of Spsb2, a Novel Immune Checkpoint Molecule, in Hepatocellular Carcinoma. Genes 2025; 16(3) doi: 10.3390/genes16030346
|
| 11 |
Rajani Rai, Kiran L. Sharma, Surbhi Sharma, Sanjeev Misra, Ashok Kumar, Balraj Mittal, Masaru Katoh. Death Receptor (DR4) Haplotypes Are Associated with Increased Susceptibility of Gallbladder Carcinoma in North Indian Population. PLoS ONE 2014; 9(2) doi: 10.1371/journal.pone.0090264
|
| 12 |
Juan Carlos Roa, N. Volkan Adsay. Molecular Surgical Pathology. 2013; doi: 10.1007/978-1-4614-4900-3_4
|
| 13 |
Gururao Hariprasad, Roopa Hariprasad, Lalit Kumar, Alagiri Srinivasan, Srujana Kola, Amit Kaushik. Apolipoprotein A1 as a potential biomarker in the ascitic fluid for the differentiation of advanced ovarian cancers. Biomarkers 2013; 18(6) doi: 10.3109/1354750X.2013.822561
|